Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07497360

Tele-assessment and Face-to-face Assessment of the 30-second Sit-stand Test in Peripheral Artery Disease

Peripheral artery disease (PAD) is a chronic and progressive condition caused by narrowing or blockage of arteries in the lower limbs due to atherosclerosis. It primarily affects adults over 50, with prevalence increasing with age, and its clinical presentation ranges from asymptomatic cases to severe ischemia that may require amputation. Intermittent claudication, characterized by exercise-induced leg pain that resolves with rest, is the most common early symptom. Impaired blood flow, poor vascularization, and muscle loss contribute to reduced lower limb strength and functional capacity, which are associated with higher morbidity and mortality.

Walking exercises is a cornerstone of PAD management, particularly for patients with no or mild symptoms, making the assessment of lower limb strength and mobility essential for designing rehabilitation programs. The 30-second sit-to-stand test is a validated and practical measure of functional capacity and walking ability. Tele-assessment using video technology has been shown to be feasible and reliable in other patient populations. Although tele-rehabilitation has been widely studied and shown to improve functional outcomes, research on tele-assessment methods to accurately evaluate patient performance and the effectiveness of rehabilitation programs is still limited, particularly in PAD patients.

This study aims to examine the reliability of the 30-second sit-to-stand test when performed via tele-assessment compared with face-to-face evaluation in patients with PAD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dokuz Eylul University Faculty of Medicine

Izmir, Balçova, 35330, Turkey (Türkiye)

Location status: Recruiting

Location contact

Kıvanç Metin, PhD

CONTACT

[email protected]

+9005322966938

About this study

Peripheral artery disease (PAD) is a progressive, chronic cardiovascular disorder characterized by narrowing and occlusion of the lower extremity arteries due to atherosclerosis. Peripheral artery disease (PAD) predominantly affects individuals over the age of 50, with its prevalence increasing progressively with age. The clinical presentation of PAD varies widely, from asymptomatic cases to severe ischemia that may necessitate amputation. Globally, PAD affects over 200 million individuals, while in Turkey, prevalence has been reported at 19.76%. Major risk factors include age, race, sex, smoking, diabetes, hypertension, dyslipidemia, and sedentary lifestyle.

Peripheral artery disease (PAD) commonly presents with intermittent claudication (IC), characterized by exercise-induced lower limb pain that resolves with rest. IC, resulting from reduced oxygen delivery to leg muscles due to arterial obstruction, manifests as pain, cramps, or numbness during activity and may progress to rest pain in advanced stages, affecting 10-35% of patients. Impaired circulation, decreased vascularization, and muscle atrophy contribute to reductions in lower extremity strength and functional capacity, which are associated with increased morbidity and mortality. The Fontaine classification system stages PAD severity from asymptomatic (Stage I) to critical limb ischemia with ulceration or gangrene (Stage IV).

Management strategies include lifestyle modification, exercise, pharmacological therapy, and surgical interventions, with exercise recognized as the most effective and cost-efficient approach for asymptomatic or mildly symptomatic patients. Assessing lower limb strength and mobility is essential for tailoring rehabilitation programs, as PAD patients show significant deficits in functional mobility and muscle strength compared to healthy individuals. The 30-second sit-to-stand test is a validated, practical measure of lower extremity function and is an independent predictor of walking capacity in PAD.

Tele-assessment methods, enabled by internet and smartphone technologies, offer remote evaluation of functional mobility using tests such as the 30-second sit-to-stand, timed up-and-go, and five-repetition sit-to-stand tests. Evidence suggests tele-assessment is reliable, feasible, and cost- and time-efficient, particularly for elderly or mobility-limited populations. However, its accuracy depends on technology quality and patient compliance. Despite studies in populations with type 2 diabetes, hip osteoarthritis, and cancer, the reliability and agreement of the 30-second sit-to-stand test via tele-assessment have not yet been evaluated in PAD patients. Investigating this could inform the development of tele-rehabilitation programs targeting lower extremity strength and functional mobility in PAD.

Therefore, this study aims to investigate the reliability of the 30-second sit-to-stand test between tele-assessment and face-to-face assessment in patients with peripheral artery disease (PAD).

Participants' lower extremity strength and functional mobility will be evaluated using the 30-second sit-to-stand test both face-to-face and online via WhatsApp on the same day. Face-to-face assessments will be conducted at the Department of Cardiovascular Surgery, Dokuz Eylül University Faculty of Medicine.

During tele-assessment, the physiotherapist and the patient will be at the Department of Cardiovascular Surgery; however, the physiotherapist will be in a separate room and will complete the evaluation synchronously via online video. Face-to-face and tele-assessments will be performed by two different physiotherapists participating in the study. The two assessments will be conducted 20-30 minutes apart, and to control for any potential test order effect, the sequence of assessments will be randomized for each participant and physiotherapist using a simple random number table.

During the face-to-face assessment, demographic and clinical information will be collected, including age, sex, body weight and height, body mass index, educational level, occupation, marital status, lifestyle habits (smoking, alcohol consumption, physical activity), medical history (past illnesses), and clinical data (year of PAD diagnosis, disease duration, medications, and comorbidities).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 18 and 65 years
  • Diagnosed with peripheral artery disease, Fontaine stage I-II, confirmed by peripheral angiography or Doppler ultrasonography
  • Willingness to participate in the study
  • Access to a smartphone and the internet

Exclusion criteria

  • Presence of orthopedic, neurological, or psychological conditions that limit physical activity
  • Neurological or musculoskeletal disorders affecting standing or walking
  • History of ischemic amputation
  • Acute inflammatory condition
  • Use of walking aids
  • Visual or hearing impairment
  • Vestibular system disorder
  • Cognitive impairment affecting cooperation
  • Severe cardiopulmonary diseases limiting walking ability
  • Major surgery or myocardial infarction within the last three months
  • Unstable coronary artery disease

Treatment and study plan

Primary outcomes

  1. Lower Extremity Function

    Time frame: From February 2026 to June 2026

    Lower extremity strength and functional mobility will be evaluated using the 30-second sit-to-stand test. Participants will sit on a 44 cm high chair with a backrest and no armrests, arms crossed over the shoulders, and will be instructed to stand and sit as many times as possible within 30 seconds. The number of complete repetitions will be recorded.

Secondary outcomes

  1. Perceived Fatigue Response to 30 Second Sit-to-Stand Test

    Time frame: February 2026 to June 2026

    Perceived fatigue will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using the Modified Borg Scale.

  2. Dyspnea Response to 30 Second Sit-to-Stand Test

    Time frame: February 2026 to June 2026

    Dyspnea severity will be assessed before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using the Modified Borg Scale.

  3. Heart Rate Response to 30 Second Sit-to-Stand Test

    Time frame: February 2026 to June 2026

    Heart rate will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using a pulse oximeter.

  4. Blood Pressure

    Time frame: February 2026 to June 2026

    Systolic and diastolic blood pressure will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test.

  5. Oxygen Saturation

    Time frame: February 2026 to June 2026

    Peripheral oxygen saturation (SpO₂) will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using a pulse oximeter.

Study contacts

Contact information is provided by the study sponsor or research team.

Cemre Emir, MSc

CONTACT

[email protected]

+9005453405480

Hazal Yakut Ozdemir, PhD

CONTACT

[email protected]

+9005074825877

Sponsors and collaborators

Lead sponsor

Izmir Democracy University

Other

Registry information

Official study title

Consistency Between Tele-Assessment and Face-to-Face Assessment Results of the 30-Second Sit-to-Stand Test in Patients With Peripheral Arterial Disease

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 27, 2026
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.